Preparing for the next pandemic
As a leading developer of molecular technologies, our aim is to make reliable, efficient, and rapid testing solutions available to as many people as possible, around the globe. Whether it’s testing for COVID, TB, or other infectious diseases, not a single person should be left behind. For the past year, QIAGEN employees worldwide have been working non-stop to support the global response to the coronavirus pandemic.
At the same time, a cross-functional task force is developing products, processes, and infrastructure to bolster our long-term preparedness. The COVID pandemic has demonstrated that speed is critical in responding to a novel pathogen, and our strategies focus on just that -- getting more tests to those that need them quickly.
We are massively increasing the production capacity of test components, strengthening the supply of critical reagents and plastics, developing fast and accurate testing technologies, and implementing stringent safety measures to protect our employees. By committing substantial resources to these efforts, we make sure we are one step ahead of the next pandemic.
Partnerships to accelerate responses to novel pathogens
New testing solutions at unprecedented speeds
A broad range of technologies for testing and research
Investment in infrastructure to increase global production
Keeping employees safe and healthy
Throughout the COVID-19 pandemic, the safety of our employees has been our priority. QIAGEN has set up a dedicated task force from all departments and locations to implement rigid safety measures including large-scale capacity for in-house PCR testing for on-site staff and visitors to protect our workforce and ensure business continuity. We have also implemented engineering and administrative controls and safe work practices.
Even as we continue to fight COVID, we must be prepared for what comes next. Epidemics and pandemics, like many public health challenges, are unpredictable but always possible. Our strategy is to prepare now for the long term – through partnerships, investments in critical infrastructure and supply chains, and innovation across a range of testing technologies. This will ensure that we are strongly equipped to support the global response to any future public health crisis.
- Visseaux, B. et al. (2020) Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection. J Clin Microbiol 58(8):e00630-20.